

September 13, 2006

Temp. Ref.: 3999.002587

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

September 13, 2006

Date

Shelley P.M. Fussey, Ph.D.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RE: U.S. Application Serial No. 10/738,404; Entitled "Selective Anti-VEGF Antibody Prodrug Methods" (As Amended); by Thorpe and Brekken; U.T. Ref.: UTSD:1412-8 US; Peregrine Family: UTS06; Our Temp. Ref.: 3999.002587

Sir:

Enclosed for filing in the above-referenced patent application are:

- (1) An Amendment; and Response to the first Official Action dated March 15, 2006, with Exhibits A-K;
- (2) A Submission of Earlier Declaration into Continuing Application, having attached thereto a copy of the Declaration of Philip E. Thorpe and Rolf A. Brekken in accordance with *In re Katz*, the original of which was submitted in parent application Serial No. 09/561,005 (now issued as U.S. Patent No. 6,703,020) on January 15, 2002;
- (3) A Request for Extension of Time of Three Months to Respond to the first Official Action dated March 15, 2006; and
- (4) A return postcard listing all these materials.

As set forth in the Request for Extension of Time to Respond to the first Official Action, a three month extension fee is believed to be due. Please deduct these fees and any other fees under 37 C.F.R. §§ 1.16 to 1.21 that may be required for any reason relating to the enclosed materials from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/3999.002587.



September 13, 2006 Page 2

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted PEREGRINE PHARMACEUTICALS, INC. CUSTOMER NO. 000052101

Shelley P.M. Fussey, Ph.D. Reg. No. 39,458 Agent for Applicants

Encl.